¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"acute fulminating type"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
  • acute intermitternt porphyria
    ±Þ¼º °£Ç漺 Æ÷¸£ÇǸ®¾Æ(Áõ)
  • acute interstitial pneumonitis
    ±Þ¼º °£Áú¼º Æó·Å(¡­ÊàòõàõøËæú).
  • acute intussusception
    ±Þ¼º ÀåÁßø(Áõ).
  • acute labyrinthitis
    ±Þ¼º ¹Ì·Î¿°, ¡­³»ÀÌ¿°
  • acute lacunar tonsillitis
    ±Þ¼º ¼±¿ÍÆíµµ¿°
  • acute laryngitis
    ±Þ¼º Èĵο°
  • acute laryngotracheal trauma
    ±Þ¼º Èĵαâ°ü¿Ü»ó
  • acute laryngotracheobronchitis
    ±Þ¼º Èĵαâ°üÁö¿°
  • acute leukemia
    ±Þ¼º ¹éÇ÷º´(¡­ÛÜúìÜ»).
  • acute monocytic leukemia
    ±Þ¼º ´Ü±¸(¼º) ¹éÇ÷º´(?ËÀË´ËÛËÑÌ´ËÓ).
  • acute myeloblastic leukemia
    ±Þ¼º °ñ¼ö¸ð¼¼Æ÷¼º ¹éÇ÷º´.
  • acute myeloblastic leukemia
    ±Þ¼º °ñ¼ö¸ð¼¼Æ÷¼º ¹éÇ÷º´.
  • acute myelocytic leukemia =AML
    ±Þ¼º °ñ¼ö±¸¼º ¹éÇ÷º´.
  • acute myelogenous leukemia
    ±Þ¼º °ñ¼ö¼º ¹éÇ÷º´(¡­ÍéâÐàõÛÜúìÜ»).
  • acute myelogenous leukemia
    ±Þ¼º °ñ¼ö¼º ¹éÇ÷º´(?Ë­ËàËÛËÑÌ´ËÓ).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
  • type II hair cell
    Á¦ Çü Åм¼Æ÷, Á¦IIÇü ¸ð¼¼Æ÷(ð¯ì£úþÙ¾á¬øà).
  • type II human T lymphotropic virus
    II Çü ÀÎ T ¸²ÇÁ¿µ¾ç¼º ¹ÙÀÌ·¯½º
  • type III human T lymphotropic virus
    IIIÇü ÀÎ t¸²ÇÁ¿µ¾ç¼º ¹ÙÀÌ·¯½º
  • type a encephalitis
    ±â¸é¼º ³ú¿°(ÐîØùàõÒàæú)
  • type a spermatogonium
    À¸¶äÁ¤Á¶¼¼Æ÷
  • type b encephalitis =japanese e.
    BÇü ³ú¿°
  • type b spermatogonium
    ´ÊÁ¤Á¶¼¼Æ÷
  • type culture
    Ç¥Áعè¾ç
  • type culture
    ´ëÇ¥(±ÕÁ¾)¹è¾ç(ÓÛøúжðúÛÆå×), Ç¥Áعè¾ç(øöñÞÛÆå×).
  • type culture
    ´ëÇ¥(±ÕÁ¾)¹è¾ç(ÓÛøúжðúÛÆå×), Ç¥Áعè¾ç(øöñÞÛÆå×).
  • type culture collection
    Ç¥ÁرÕÁÖ¼ö·Ï(¡­Ð¶ñ»â¥ÒÓ).
  • type i hair cell
    Á¶·Õ¹ÚÅм¼Æ÷
  • type ii hair cell
    ¿øÁÖÅм¼Æ÷
  • type of respiration
    È£ÈíÇü(û¼ýåúþ).
  • type species
    Ç¥ÁرÕÁ¾(øöñÞжðú).
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 13
CKMM creatine kinase, muscle type
CNF chronic nodular fibrositis; congenital nephrotic syndrome of the Finnish [type]
CPK-BB creatine phosphokinase, brain-type
CR1 complement receptor type 1
CRPS complex regional pain syndrome [type I and II]
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 13
ACI Acute coronary insufficiency
AD Acute diarrhea
ADEM Acute disseminated encephalomyelitis
AEP Acute eosinophilic pneumonia
AECB Acute exacerbation of chronic bronchitis
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • acute phase protein
    ±Þ¼º±â ´Ü¹éÁú
    °¨¿°À̳ª Á¶Á÷ ¼Õ»óÀÌ ÀÖÀ» ¶§ Á¤»óº¸´Ù 2-100¹è Á¤µµ Áõ°¡ÇÏ´Â Ç÷Àå ´Ü¹éÁúÀ» ÃÑĪÇÏ¿© APP¶ó°í ÇÏ¸ç ¼±Ãµ¼º ¸é¿ª¿¡ °ü¿©ÇÑ´Ù.
  • acute phase reaction
    ±Þ¼º±â ¹ÝÀÀ
  • acute phase serum
    ±Þ¼º º´±â Ç÷û
  • acute pneumonia
    ±Þ¼º Æó·Å
    ¹ÙÀÌ·¯½º, ¼¼±Õ µî¿¡ ÀÇÇØ¼­ »ý±â´Â Æó ½ÇÁúÀÇ ±Þ¼º ¿°ÁõÀÌ°í º´º¯ÀÇ Áß½ÉÀº ÆóÆ÷ »óÇÇ, ¼¼Æ÷ °­¿¡ ÀÖÀ¸¸ç, ÆóÆ÷³»¿¡ ´Ù·®ÀÇ Ä§Ãâ¹°ÀÌ Ãæ¸¸ÇØ X-¼± Çʸ§ »ó¿¡¼­´Â ±â°üÁö °­À» Á¦¿ÜÇÏ°í ±ÕµîÇÑ ±×¸²ÀÚ·Î µÚµ¤ÀδÙ. Àü¿¡´Â °¨¿° Áúȯ Áß »óÀ§¸¦ Â÷ÁöÇϰí ÀÖ¾ú´Âµ¥ Ç×»ý ¹°ÁúÀÇ µîÀåÀ¸·Î °Ý°¨Çß´Ù. ÃÖ±Ù¿¡´Â ¿ø³»°¨¿°¿¡ µû¸¥ ³­Ä¡ÀÇ ±×¶÷ À½¼º±Õ °¨¿°ÀÌ Áõ°¡ Ãß¼¼¿¡ ÀÖ´Ù.
  • acute poliomyelitis
    ±Þ¼º ȸ¹éô¼ö¿°, ±Þ¼º ¼Ò¾Æ¸¶ºñ
    »ê¹ßÀûÀ¸·Î ¹ß»ýÇÏ´Â ±Þ¼º ¹ÙÀÌ·¯½º ÁúȯÀ¸·Î ¹ß¿­, ÀεΠ¹ßÀû, µÎÅë, ±¸Åä µîÀ» Ư¡À¸·Î ÇÏ°í ¸ñ´ú¹Ì¿Í µî ÂÊ ºÎºÐÀÇ °­Á÷À» µ¿¹ÝÇÑ´Ù.
  • acute poststreptococcal glomerulonephritis
    ±Þ¼º ¿¬¼â»ó ±¸±Õ¼º »ç±¸Ã¼ ½Å¿°
    A±º ¿¬¼â»ó ±¸±Õ °¨¿°ÀÌ ¿øÀÎÀÌ µÇ¾î ¹ß»ýÇÏ´Â ±Þ¼º ½Å¿°ÀÌ´Ù. ¿¬¼â»ó ±¸±Õ¿¡ ÀÇÇÑ Æíµµ¿° µîÀÌ Ä¡À¯µÇ¾î¼­ 1-2ÁÖ ÈÄ¿¡ µ¹¿¬ ºÎÁ¾, ÇÌ´¢, °íÇ÷¾Ð µîÀ» µ¿¹ÝÇØ¼­ ¹ßº´ÇÑ´Ù. ¼Ò¾Æ¿¡ ¸¹ÀÌ ¹ßº´Çϳª ¼ºÀο¡°Ôµµ µå¹°Áö´Â ¾ÊÀ¸¸ç, ¾à 90%´Â 1-2°³¿ù ÈÄ¿¡ ¿ÏÀüÈ÷ Ä¡À¯µÈ´Ù. Ç÷û ASLO °ªÀÇ »ó½Â°ú Ç÷û º¸Ã¼°¡ÀÇ °¨¼Ò°¡ Áø´Ü¿¡ µµ¿òÀÌ µÈ´Ù. ÀÌ Áõ»óÀº ¿¬¼â»ó ±¸±ÕÀÇ Ç׿ø°ú ±× Ç×ü¿¡ ÀÇÇÑ ¸é¿ª º¹ÇÕü ½Å¿°ÀÌ´Ù. ƯÈ÷ ¼Ò¾Æ¿¡¼­´Â ±Þ¼º±â¿¡ °íÇ÷¾Ð¿¡ ÀÇÇÑ ½ÉºÎÀü, °æ·ÃÀ» ÀÏÀ¸Å°±â ½±±â ¶§¹®¿¡ ÁÖÀǸ¦ ¿äÇÑ´Ù.
  • acute pseudomembranous candidosis
    ±Þ¼º À§¸·¼º ĵµð´ÙÁõ
  • acute psychologic distress
    ±Þ¼ºÀÇ Á¤½ÅÀû °íÅë
  • acute pulpitis
    ±Þ¼º Ä¡¼ö¿°
    Ä¡¼öÀÇ ±Þ¼º ¿°ÁõÀÌ´Ù. Ä¡¾Æ¿ì½ÄÁõÀ¸·Î ÀÕµû¶ó ¹ß»ýÇÏ´Â °Í°ú ¿Ü»óÀÌ ¿øÀÎÀÎ °ÍÀ¸·Î ±¸ºÐÇÑ´Ù. ¸ðµÎ ½ÉÇÑ ÅëÁõÀÌ ÁÖµÈ Áõ»óÀÌ´Ù. ÈÄÀÚ¿¡ À־´Â ÁøÅëÁ¦ Åõ¿©·Î Áõ»óÀÌ °¡¶ó¾É´Â °ÍÀÌ ¸¹Àºµ¥, ÀüÀÚÀÇ °æ¿ì ÁøÅëÁ¦·Î È¿°ú°¡ ¾ø°í, ¹ßÄ¡ÇÏÁö ¾ÊÀ¸¸é ¾È µÈ´Ù.
  • acute pyelonephritis
    ¸¸¼º ½Å¿ì½Å¿°
    ¸¸¼ºÀÇ ¼¼´¢°ü °£ÁúÀÇ ¿°Áõ°ú ½Å Á¶Á÷ÀÇ ¹ÝÈç ¹× ½Å¹è¿Í ½Å¿ìÀÇ º´º¯À» µ¿¹ÝÇÏ´Â ÁúȯÀÌ´Ù. ¸¸¼º ½Å¿ì½Å¿°Àº ¸»±â ½Å ÁúȯÀÇ Áß¿äÇÑ ¿øÀÎÀ¸·Î ½Å ÀÌ½Ä È¯ÀÚ³ª Åõ¼® ȯÀÚÀÇ 11-20%¸¦ Â÷ÁöÇÑ´Ù. ¸¸¼º ½Å¿ì½Å¿°Àº ¸¸¼º Æó¼â¼º ½Å¿ì½Å¿°°ú ¿ª·ù¼º ½Åº´ÁõÀ¸·Î ³ª´«´Ù.
  • acute radiation sickness
    ±Þ¼º ¹æ»ç¼±Áõ
    ±Þ¼º ¹æ»ç¼± Àå¾Ö °¡¿îµ¥ Àü½Å Áõ»óÀ¸·Î¼­ ³ªÅ¸³ª´Â °ÍÀ» ¸»ÇÑ´Ù. Áï ÇÇ·Î, ½Ä¿å °¨Åð, ¿À½É, ±¸Åä µîÀÇ Áõ»óÀÌ ³ªÅ¸³­´Ù. ´ëºÎºÐ Àü½Å¿¡ ÇÇÆøÇÑ °æ¿ì¿¡ »ý±â´Âµ¥ ±¹¼Ò ÇÇÆøÀÌ¶óµµ ¾çÀÌ ¸¹À» ¶§¿¡´Â »ý±ä´Ù. ƯÈ÷ ¹æ»ç¼± Ä¡·áÀÇ °æ¿ì¿¡µµ ³ú³ª º¹ºÎ¿¡ Á¶»çÇÑ °æ¿ì¿¡ ÀÏÀ¸Å°±â ½±´Ù.
  • acute rejection vasculitis
    ±Þ¼º °ÅºÎ Ç÷°ü¿°
    ÀÌ½Ä ÈÄ ¸î °³¿ù ³»¿¡ ³ªÅ¸³ª°Å³ª ¸é¿ª¾ïÁ¦¿ä¹ýÀ» Áß´ÜÇßÀ» ¶§ ¹ß»ýÇÒ ¼ö ÀÖ´Ù. ÀÌ·¯ÇÑ È¯ÀÚ´Â ÀÌ½Ä Àå±âÀÇ ±â´ÉÀå¾Ö°¡ ÀÌ½Ä ¼ö¼ú ÈÄ °©Àڱ⠳ªÅ¸³ª¼­ Áö¼Ó¼ºÀ» º¸ÀÌ¸ç °í´ÜÀ§ÀÇ ¸é¿ª¾ïÁ¦¿ä¹ý¿¡ ÀÇÇØ¼­µµ Àß Ä¡À¯µÇÁö ¾Ê´Â´Ù.
  • acute respiratory distress syndrome
    ±Þ¼º È£Èí°ï¶õ ÁõÈıº
    ¼ºÀΠȣÈíºÎÀü, ¼ï Æó, ¹Ì¸¸¼º ÆóÆ÷ ¼Õ»ó, ±Þ¼º ÆóÆ÷ ¼Õ»ó, ¿Ü»ó¼º ÀæÀº Æó µîÀÌ ÀÖ´Ù. ¹Ì¸¸¼ºÀ¸·Î ÆóÆ÷ ¸ð¼¼Ç÷°üÀÌ ¼Õ»óÀ» ÀÔ¾î ÃÊ·¡µÇ¸ç ÀÓ»óÀûÀ¸·Î´Â ±Þ°ÝÈ÷ »ý±ä ½ÉÇÑ È£Èí°ï¶õ, ºó¸Æ, û»öÁõ ¹× »ê¼Ò¿ä¹ý¿¡ ¹ÝÀÀÇÏÁö ¾Ê´Â µ¿¸Æ Àú»ê¼ÒÁõ µîÀ» Ư¡À¸·Î ÇÑ´Ù.
  • acute rheumatic arthritis
    ±Þ¼º ·ù¸¶Æ¼½º¼º °üÀý¿°
  • acute rheumatic polyarthritis
    ±Þ¼º ·ù¸¶Æ¼½º¼º ´Ù¹ß °üÀý¿°, ±Þ¼º ·ù¸¶Æ¼½º¼º ´Ù¹ß¼º °üÀý¿°
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 13
glycogen storage disease type I <disease> An autosomal recessive disease in which gene expression of glucose-6-phosphatase is absent, resulting in hypoglycaemia due to lack of glucose production.
Accumulation of glycogen in liver and kidney leads to organomegaly, particularly massive hepatomegaly. Increased concentrations of lactic acid and hyperlipidemia appear in the plasma. Clinical gout often appears in early childhood.
Inheritance: autosomal recessive.
(12 Dec 1998)
glycogen storage disease type II <disease> Glycogenosis due to alpha-1,4-glucosidase (acid maltase) deficiency. It affects muscle, heart, and other organs.
(12 Dec 1998)
glycogen storage disease type III <disease> An autosomal recessive metabolic disorder due to deficient expression of amylo-1,6-glucosidase (one part of the glycogen debranching enzyme system).
The clinical course of the disease is similar to that of glycogen storage disease type I, but milder. Massive hepatomegaly, which is present in young children, diminishes and occasionally disappears with age. Levels of glycogen with short outer branches are elevated in muscle, liver, and erythrocytes. Six subgroups have been identified, with subgroups type IIIa and type IIIb being the most prevalent.
Inheritance: autosomal recessive
(12 Dec 1998)
glycogen storage disease type IV <disease> An autosomal recessive metabolic disorder due to a deficiency in expression of branching enzyme (alpha-1,4-glucan-6-alpha-glucosyltransferase), resulting in an accumulation of abnormal glycogen with long outer branches. Clinical features are muscle hypotonia and cirrhosis. Death from liver disease usually occurs before age 2.
Inheritance: autosomal recessive
(12 Dec 1998)
glycogen storage disease type V <disease> Glycogenosis due to muscle phosphorylase deficiency. Characterised by painful cramps following sustained exercise.
Inheritance: autosomal recessive
(12 Dec 1998)
glycogen storage disease type VI <disease> A hepatic glycogen storage disease in which there is an apparent deficiency of hepatic phosphorylase activity. However, studies have not been able to distinguish between phosphorylase deficiency and phosphorylase kinase deficiency in patients with hepatic glycogenosis.
(12 Dec 1998)
glycogen storage disease type VII <disease> An autosomal recessive muscle glycogen storage disease in which there is deficient expression of muscle phosphofructokinase activity, resulting in increased concentrations of glucose-6-phosphate and fructose-6-phosphate and low concentrations of fructose-1,6-diphosphate in muscle tissue.
Glycogen storage in muscle is increased, perhaps due to activation of glycogen synthase by accumulated glucose-6-phosphate. It has been proposed that shunting of glucose-6-phosphate and fructose-6-phosphate into the pentose phosphate pathway may result in increased synthesis of purines and pyrimidines, causing hyperuricaemia and gout.
Erythrocytes from patients may show decreased phosphofructokinase activity and 2,3-diphosphoglycerate deficiency. Exercise intolerance is present and severe congenital muscular dystrophy has been reported.
Inheritance: autosomal recessive
(12 Dec 1998)
glycogen storage disease type VIII <disease> An x-linked recessive hepatic glycogen storage disease resulting from lack of expression of phosphorylase-b-kinase activity. Symptoms are relatively mild; hepatomegaly, increased liver glycogen, and decreased leukocyte phosphorylase are present. Liver shrinkage occurs in response to glucagon.
Inheritance: X-linked recessive
(12 Dec 1998)
V-type ATPase <enzyme> From eukaryotic endomembrane systems, including vacuoles, lysosomes, golgi apparatus, chromaffin granules and coated vesicles. One of three major classes of ion transport ATPase, characterised by a multi subunit structure and a lack of a phosphorylated intermediate.
Found in archaebacteria but not eubacteria, in the intracellular acidic vacuoles and in some proton pumping epithelia (e.g. Intercalated cells of kidney). A complex enzyme encoded by several genes, involved in ion translocation but does not act via phosphorylated enzyme intermediate
See: P-type ATPase.
Registry number: EC 3.6.1.-
Synonym: atpase, v-type, atpase, vacuolar, vacuolar atpase, v-atpase, vacuolar h+-atpase, vacuolar membrane h(+)-atpase, vha55 gene product, vma16 gene product
(26 Jun 1999)
Gm type <immunology> Genetically determined allotypic antigens found on IgG of some individuals.
(18 Nov 1997)
Golgi type II neuron <physiology> Nerve cells with short axons which ramify in the gray matter.
(05 Mar 2000)
Golgi type I neuron <physiology> Nerve cells whose long axons leave the gray matter of which they form a part.
(05 Mar 2000)
membrane-type 3 matrix metalloproteinase <enzyme> Sm3 is a soluble form of mt3-mmp, probably an alternatively sliced variant.
Registry number: EC 3.4.24.-
Synonym: mt3-mmp, sm3-mmp
(26 Jun 1999)
membrane-type 4 matrix metalloproteinase <enzyme> Cloned from breast carcinoma.
Registry number: EC 3.4.24.-
Synonym: mt4-mmp, mmp-17 gene product, mmp-17
(26 Jun 1999)
membrane-type matrix metalloproteinase <enzyme> Activates gelatinase a; isolated from a human placenta cdna gene library; contains a transmembrane domain; do not use for any other numbered matrix metalloproteinases; genbank d26512
Registry number: EC 3.4.24.-
Synonym: mt-mmp, mmp-x1 protein, matrix metalloproteinase, membrane-type, mmp14 gene product, mmp-14 gene product, mt1-mmp, matrix metalloproteinase 14, mt2-mmp, mmp15 gene product, mmp16 gene product
(26 Jun 1999)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 13
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 13
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 13
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 13
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 13
ÅëÇÕ°Ë»ö ¿Ï·á